These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18647662)

  • 1. Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results.
    Major P; Greenberg E; Khan A; Thiele EA
    Epilepsy Behav; 2008 Oct; 13(3):557-9. PubMed ID: 18647662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive and negative psychotropic effects of levetiracetam.
    Helmstaedter C; Fritz NE; Kockelmann E; Kosanetzky N; Elger CE
    Epilepsy Behav; 2008 Oct; 13(3):535-41. PubMed ID: 18583196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral effects of levetiracetam mitigated by pyridoxine.
    Davis GP; McCarthy JT; Magill DB; Coffey B
    J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):209-11. PubMed ID: 19364300
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
    von Stuelpnagel C; Holthausen H; Kluger G
    Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.
    Hirsch LJ; Arif H; Buchsbaum R; Weintraub D; Lee J; Chang JT; Resor SR; Bazil CW
    Epilepsia; 2007 Jul; 48(7):1351-9. PubMed ID: 17573925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.
    Perry MS; Benatar M
    Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of Levetiracetam-Induced Behavioral Side Effects by Pyridoxine. A Randomized Double Blind Controlled Study.
    Mahmoud A; Tabassum S; Al Enazi S; Lubbad N; Al Wadei A; Al Otaibi A; Jad L; Benini R
    Pediatr Neurol; 2021 Jun; 119():15-21. PubMed ID: 33823377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study.
    López-Góngora M; Martínez-Domeño A; García C; Escartín A
    Epileptic Disord; 2008 Dec; 10(4):297-305. PubMed ID: 19017572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.
    Romoli M; Perucca E; Sen A
    Epilepsy Behav; 2020 Feb; 103(Pt A):106861. PubMed ID: 31917143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levetiracetam as a treatment option in non-convulsive status epilepticus.
    Rupprecht S; Franke K; Fitzek S; Witte OW; Hagemann G
    Epilepsy Res; 2007 Mar; 73(3):238-44. PubMed ID: 17161587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of levetiracetam on cognition: a non-interventional surveillance study.
    Helmstaedter C; Witt JA
    Epilepsy Behav; 2008 Nov; 13(4):642-9. PubMed ID: 18707022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
    Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
    Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of paradoxical levetiracetam effect is increased in mentally retarded patients.
    Szucs A; Clemens Z; Jakus R; Rásonyi G; Fabó D; Holló A; Barcs G; Kelemen A; Janszky J
    Epilepsia; 2008 Jul; 49(7):1174-9. PubMed ID: 18479387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and efficacy of oral loading of levetiracetam.
    Koubeissi MZ; Amina S; Pita I; Bergey GK; Werz MA
    Neurology; 2008 May; 70(22 Pt 2):2166-70. PubMed ID: 18505995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin B6 decreases the risk of levetiracetam discontinuation in children with epilepsy: A retrospective study.
    Lob K; Bassell-Hawkins J; Patil R; Nie D; Bartolini L
    Epilepsy Behav; 2022 Sep; 134():108839. PubMed ID: 35839645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of levetiracetam because of behavioral side effects: a case-control study.
    White JR; Walczak TS; Leppik IE; Rarick J; Tran T; Beniak TE; Matchinsky DJ; Gumnit RJ
    Neurology; 2003 Nov; 61(9):1218-21. PubMed ID: 14610123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridoxine Add-On Treatment for the Control of Behavioral Adverse Effects Induced by Levetiracetam in Children: A Case-Control Prospective Study.
    Marino S; Vitaliti G; Marino SD; Pavone P; Provvidenti S; Romano C; Falsaperla R
    Ann Pharmacother; 2018 Jul; 52(7):645-649. PubMed ID: 29442544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age.
    Krief P; Li Kan ; Maytal J
    J Child Neurol; 2008 May; 23(5):582-4. PubMed ID: 18448575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.